Application of the genO‑hOX40 mouse model

Useful applications for researchers working on different biomedical fields, such as immuno-inflammation, oncology and autoimmunity:

  • Assess the efficacy of OX40-targeting compounds
    • Performe tumor growth inhibition assays
    • Evaluate OX40 antagonists for the treatment of autoimmune and inflammatory conditions
  • Gain insights into the mode of action (MoA) of diverse constructs and their potential therapeutic benefits
  • Perform long-term studies, as immunological memory is observed following treatment

Features

  • Physiological regulation and expression pattern of the human OX40
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

Anti-tumor efficacy and tumor-specific immunological memory were proven in MC38 and MB49 tumor models.

Clients

No items found.

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Validation data

Discover related products to

genO‑hOX40

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD-1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

genO‑hCD39

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

genO‑hPD-1

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

genO‑hPD-1/hPD-L1

The genO‑hPD‑1/hPD‑L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

genO‑hPD‑1/hLAG3

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

genO‑hVISTA

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Preclinical humanized genO‑hOX40 mouse model

Get in touch about

Let us know how we can help